|
|||||||||||||||
|
||||||||||||||||||
Data:2009-12-12 2:34
Source: Broadcasting Corporation of Information Chen Zhou Jie
China's new government proposed a "harmonious society" development goals, "the common people hard to see a doctor of coverage" of social problems has been the government's attention. Medical Reform Coordination Group will set up a specialized health care market regulation thematic study groups, supervision of the circulation area, the formation of a new price system. Compressed medical supply chain, first of all to benefit pharmaceutical distribution companies, this is the recent Sinopharm shares, Nanjing, and Shanghai Pharmaceutical rose medical reasons, in fact, medical health-care reform the same used for the main production of medicines used for business. Especially those with their own unique brand, R & D resources such as cost control and higher viability of the pharmaceutical companies will bring about change in the medical industry major reshuffle in the grab more market, growth prospects, such as the 600,572 CONBA.
A number of natural herbal products to enter the health insurance giant catalog
CONBA (600,572): The company relies on Group's largest shareholder CONBA strong research and brand to expand capacity, by virtue of Zhejiang Province as the only production base of herbal extract resources, establish pollen, Ginkgo biloba, Pueraria lobata, Yuan Hu, medicine new formulation with the fungi and six herbal product R & D direction, implementation and completion of branded prescription drugs and the marketing sub-line operation, establishment of brand-name drugs and prescription drugs professional development of new marketing system. Because times change, and heavy-class best-selling drug types are continuously changing, the new product is the enterprise survival and development of an important source of inspiration. Diseases of modern civilization have replaced infectious disease as the greatest threat to human diseases, such diseases, including hypertension, hyperlipidemia, diabetes, mental illness and so on. The needs of modern people not only depend on the medical efficacy of health functions at the same time pay attention to. Therefore, natural botanicals in the treatment of these diseases have natural advantages, the international herbal market share has reached 30 billion U.S. dollars, and over 20% annual growth rate. The forefront of the company's leading product safety Kang Bullock film, Taponin card Ginkgo biloba, days Baokang brand Puerarin, Wuling Capsule, etc. both in the domestic market with high brand awareness and market share, became the company's main source of profits. Zhe Bei chloride compound liquorice tablets and levofloxacin hydrochloride injection, a subsidiary of Hangzhou CONBA of glipizide sustained-release capsules, pioglitazone hydrochloride tablets, doxazosin mesylate tablets (must be Jashin) and the Jolly Pharmaceutical Wuling Capsule, etc. are incorporated into the "national basic medical insurance and industrial injury insurance, medicine directory."
Independent intellectual property rights reinforce the growth of high-brand recognition on the basis of the majority shareholder's specializes in traditional Chinese medicine and natural medicine research and development of Zhejiang Institute of Chinese medicine and natural medicine, the company increased R & D efforts. Company is committed to continuous introduction of new products through to get the space for development, high-quality products Pollock Yasukata rape pollen is a major component of Chinese medicine for the protection of species, for 20 years gradually increase the market share is recommended by the national pharmacy OTC prostatitis and benign prostatic hyperplasia drugs first brand of Chinese medicine is the only category in which brand-name products, the first three quarters of this year the forefront of health continue to maintain more than 20% growth. Ginkgo biloba, another brand Taponin successfully developed China's first ginkgo biloba extract, ginkgo biloba Ginkgo Flavonol-rich and the ginkgo terpene lactones, mainly for the treatment of cardio-cerebral vascular diseases, aging, the market demand, as Taponin The first successful study of ginkgo leaf products with high brand loyalty. OTC New Products such as the 8 until the end of the OTC sale CONBA card sales Ditong rhinitis has also been made of water begun to make progress, a subsidiary of Jolly Pharmaceutical Products Wuling Wuling capsule powder and a class of drugs are the State Chinese Medicine its bacteria and production process for an exclusive first at home and abroad, its technological achievements of the intellectual property rights for the exclusive Jolly Pharmaceutical development prospect is broad.
Directed additional profitability has improved rapidly expand the size of largest shareholder group is the actual controller CONBA Mr. Hu Jiqiang-hand development and growth of the modern herbal research and development, manufacturing and the chemical compound classes in preparation possess modern technology with core competencies of large pharmaceutical companies group. Companies step up to CONBA group of related industries within the herbal resources of integration, optimization and management of the intensity of incentives to achieve the Group's operating assets, listed as a whole. Has the transferee CONBA group medical health care products Co., Ltd. 100% stake, also plans to issue no more than 4280 non-public shares acquired 90% interest in Jinhua CONBA assets, the acquisition is completed, CONBA to scale, product Line richer. In the first three quarters, the company main business revenue fell 7.15 percent of the cases, the net profit grew 35.3%, to achieve earnings per share were 0.25 yuan. That internal resource integration has yielded results. The company also developed a management stock option incentive plan, which will benefit the company's interests and the management of the close combination of management has a bigger and stronger the company's strong motivation. If the company has directed issuance in late 2006 or early 2007, then 2007 onwards the company's sales revenue and net profit is expected to be faster growth expected in 2007 will reach 0.55-0.65 yuan per share, the company's profitability will rapidly increase , significantly underestimated in present value.
Poised to fully convergent triangular After finishing a breakthrough is imminent rise in the first half of this year, the unit was created in July entered the finishing phase, Su Liang continued to drop, short-term decline in more than 25%, the risk is fully released. The stock then repeated in six months finishing line party poised, although the broader market bottom during the pick-up hit a new high, the company also disclosed additional orientation and asset acquisitions, good news, the stock was unmoved, and maintained a pattern of higher-band shock , from the Zhou K-line portfolio of view, the Unit to build a triangular pattern of convergence has now run into the triangle top of the K-line portfolio of three weeks with yang, volume and price with the ideal, from the Japanese K-line analysis, the unit shot up last week, has declined , in the 60-day moving average to obtain support, followed by first beating the overall market rebound, a strong clear that the market outlook is expected to break up and challenge previous high point, investors can take an active interest.
